Applied Molecular Transport to Present at Oppenheimer 31st Annual Healthcare Conference

Rhea-AI Summary

Applied Molecular Transport Inc. (Nasdaq: AMTI) will feature CEO Tahir Mahmood in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021, at 11:20 a.m. ET. The event will provide insights into AMT's innovative approaches in developing oral biologic products targeting autoimmune and inflammatory diseases. A live webcast will be available on the company's events page, with a replay for 30 days post-event. AMT’s technology enables enhanced transport across the intestinal barrier, marking a significant advancement in biopharmaceutical design.

SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the Oppenheimer 31^st Annual Healthcare Conference on Thursday, March 18, 2021 at 11:20 a.m. ET.

A live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days following the event.

About Applied Molecular Transport Inc.

Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly oral forms that are designed to either target local gastrointestinal tissue or enter systemic circulation to precisely address the relevant biology of a disease.

AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.

Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
achang@appliedmt.com

Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

FAQ

When will AMTI CEO Tahir Mahmood speak at the Oppenheimer 31st Annual Healthcare Conference?

Tahir Mahmood will speak at the conference on March 18, 2021, at 11:20 a.m. ET.

How can I watch the fireside chat for AMTI at the Oppenheimer conference?

A live webcast of the fireside chat will be available on AMTI's events page.

What innovative approaches is AMTI using in biopharmaceutical development?

AMTI is leveraging proprietary technology to develop oral biologic products targeting autoimmune and inflammatory diseases.

What is the focus of AMTI's product candidates?

AMTI's product candidates focus on treating autoimmune, inflammatory, and metabolic diseases with patient-friendly oral forms.

Where is the headquarters of Applied Molecular Transport Inc. located?

AMTI's headquarters and GMP manufacturing facilities are located in South San Francisco, CA.